Additionally, to analyze which genes caused primary drug resistance to anti-PD1 treatment, we sequenced 289 nanostring panel RNA and found increased GUSB expression in the anti-PD1 resistance group, thus finding new predictive molecules and therapeutic targets for anti-PD1 therapy in HCC. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.